Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-23

Amphastar Pharmaceuticals, Inc. (AMPH)

CEO Jack Yongfeng Zhang was paid $8,309,350 in fiscal year 2025, ↑ up 7.4% from fiscal year 2024, the 38th percentile of its disclosed peer group (SEC filing 0001297184-26-000023 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,309,350 ↑
Jack Yongfeng Zhang total, FY2025
38th
CEO pay percentile vs peers
135:1
CEO-to-median pay ratio
91.85%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jack Yongfeng Zhang (Chief Executive Officer, President, Chief Scientific Officer and Director), FY2025 total compensation $8,309,350 (base salary $950,911) [exec_comp, SEC accession 0001297184-26-000023, filed 2026-04-13]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

AMPH's next annual pay disclosure, estimated April 12, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jack Yongfeng Zhang$950,911$329,747$3,301,981$3,302,024$361,000—$63,687$8,309,350
Chief Executive Officer, President, Chief Scientific Officer and Director
Mary Ziping Luo775,120288,9231,391,9761,392,030128,000—55,0294,031,078
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
William Peters649,846370,3081,043,9821,044,02273,000—57,5243,238,682
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
Rong Zhou717,587280,475701,500701,51398,000—43,5592,542,634
Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Jacob Liawatidewi499,909265,200591,979592,02647,000—41,7422,037,856
Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and Director

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jack Yongfeng Zhang$8,309,350$7,734,759$7,722,768↑ +574,591
Mary Ziping Luo4,031,0783,798,6983,774,647↑ +232,380
William Peters3,238,6822,910,8612,893,300↑ +327,821
Rong Zhou2,542,6342,127,9182,025,312↑ +414,716
Jacob Liawatidewi2,037,8561,821,7621,776,099↑ +216,094

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Amphastar Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AMPH reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Amphastar Pharmaceuticals, Inc. Peer Teardown Report

$8,309,350 Jack Yongfeng Zhang total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of September 23, 2026 · Source: 0001297184-26-000023 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for AMPH

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
AMPHon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order AMPH

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against AMPH
13 companies name AMPH as a compensation peer

Each company listed discloses AMPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Amphastar Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
David GaughIndependent Director$284,727
Diane GerstIndependent Director$327,750
Floyd F. PetersenIndependent Director$325,000
Gayle DeflinIndependent Director$340,000
Howard LeeIndependent Director$333,500
Michael A. ZasloffIndependent Director$331,000
Richard PrinsLead Independent Director$377,500
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
David GaughDirector2026-06-01A17,365$0$0Derivative, Class A CommonForm 4 ↗
Diane GerstDirector2026-06-01A17,36500Derivative, Class A CommonForm 4 ↗
Howard LeeDirector2026-06-01A8,14300CommonForm 4 ↗
Gayle DeflinDirector2026-06-01A17,36500Derivative, Class A CommonForm 4 ↗
Gayle DeflinDirector2026-06-01A8,14300CommonForm 4 ↗
Diane GerstDirector2026-06-01A8,14300CommonForm 4 ↗
Michael A. ZasloffDirector2026-06-01A17,36500Derivative, Class A CommonForm 4 ↗
Michael A. ZasloffDirector2026-06-01A8,14300CommonForm 4 ↗
Howard LeeDirector2026-06-01A17,36500Derivative, Class A CommonForm 4 ↗
Richard PrinsDirector2026-06-01A17,36500Derivative, Class A CommonForm 4 ↗
Richard PrinsDirector2026-06-01A8,14300CommonForm 4 ↗
David GaughDirector2026-06-01A8,14300CommonForm 4 ↗
Howard LeeDirector2026-06-02D7691814,188CommonForm 4 ↗
Anthony T. PierceDirector2026-07-09A16,64600Derivative, Class A CommonForm 4 ↗
Anthony T. PierceDirector2026-07-09A7,88600CommonForm 4 ↗
William J. PetersDirector2026-08-07D5,05300Derivative, Class A CommonForm 4 ↗
William J. PetersDirector2026-08-07D8,18022183,886CommonForm 4 ↗
William J. PetersDirector2026-08-07A5,0532099,999CommonForm 4 ↗
Richard PrinsDirector2026-08-11D7,97320161,852CommonForm 4 ↗
Rong ZhouSENIOR EVP, PRODUCTION CENTER2026-09-02D3,1872475,306CommonForm 4 ↗
Rong ZhouSENIOR EVP, PRODUCTION CENTER2026-09-16D10,00000Derivative, Class A CommonForm 4 ↗
Rong ZhouSENIOR EVP, PRODUCTION CENTER2026-09-16A10,00013133,500CommonForm 4 ↗
Rong ZhouSENIOR EVP, PRODUCTION CENTER2026-09-16D10,00024239,404CommonForm 4 ↗
William J. PetersDirector2026-09-21D4,13925103,475CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mary Ziping LuoRSU2025-03-10——48,996—$1,391,976
William PetersRSU2025-03-10——36,747—1,043,982
Jack Yongfeng ZhangRSU2025-03-10——116,226—3,301,981
Rong ZhouRSU2025-03-10——24,692—701,500
Jacob LiawatidewiRSU2025-03-10——20,837—591,979
Jacob LiawatidewiOPTION2025-03-10——44,253—592,026
Rong ZhouOPTION2025-03-10——52,437—701,513
Jack Yongfeng ZhangOPTION2025-03-10——246,821—3,302,024
William PetersOPTION2025-03-10——78,039—1,044,022
Mary Ziping LuoOPTION2025-03-10——104,052—1,392,030
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mary Ziping Luo$1,391,976$0$1,392,0300.0%
William Peters1,043,98201,044,0220.0%
Jack Yongfeng Zhang3,301,98103,302,0240.0%
Rong Zhou701,5000701,5130.0%
Jacob Liawatidewi591,9790592,0260.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
William PetersOption12,68534.74—
Jack Yongfeng ZhangOption246,82128.41—
Jack Yongfeng ZhangRSU19,228—514,926
William PetersRSU36,747—984,085
Mary Ziping LuoOption42,83146.68—
Mary Ziping LuoRSU17,150—459,277
Jacob LiawatidewiOption13,43635.13—
Jack Yongfeng ZhangRSU40,691—1,089,705
Rong ZhouRSU24,692—661,252
Rong ZhouRSU7,564—202,564
Jacob LiawatidewiRSU5,664—151,682
Rong ZhouRSU3,414—91,427
Jacob LiawatidewiRSU2,878—77,073
Jack Yongfeng ZhangOption44,36534.74—
Jack Yongfeng ZhangOption85,74435.13—
William PetersOption78,03928.41—
Mary Ziping LuoRSU8,103—216,998
Jack Yongfeng ZhangRSU116,226—3,112,532
Mary Ziping LuoRSU48,996—1,312,113
Rong ZhouOption7,87934.74—
Jack Yongfeng ZhangRSU48,232—1,291,653
Jacob LiawatidewiRSU20,837—558,015
Mary Ziping LuoRSU20,332—544,491
William PetersRSU14,580—390,452
William PetersRSU11,962—320,342
Rong ZhouRSU9,390—251,464
Jacob LiawatidewiRSU6,376—170,749
Mary Ziping LuoOption36,13935.13—
William PetersOption30,71646.68—
Jacob LiawatidewiOption44,25328.41—
Rong ZhouOption19,78346.68—
Rong ZhouOption52,43728.41—
Jacob LiawatidewiRSU8,065—215,981
William PetersRSU5,497—147,210
Mary Ziping LuoOption18,69634.74—
Jack Yongfeng ZhangOption101,60446.68—
William PetersOption25,20835.13—
Rong ZhouOption15,94135.13—
Mary Ziping LuoOption104,05228.41—
Jacob LiawatidewiOption6,64134.74—
05

Incentive-plan design — the Compensation Discussion & Analysis

The objectives of our executive compensation program are to encourage high performance, promote accountability, align employee interests with the interests of the Company's stockholders, and attract, develop, and retain talented leadership to serve the long-term best interest of the Company.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantWillis Towers Watson (WTW)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingFalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0132,585,9082,779,281111,80391.85%Passed
20252025-06-0235,585,0001,815,52199,38094.89%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0191.85%a
20252025-06-0294.89%b

a. Approved under the standard stated in the filing — “Please note that abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote "against" the proposal.”.

b. Approved under the standard stated in the filing — “Please note that abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote "against" the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)135 : 1
CEO total compensation$8,309,350
Median employee compensation$61,658
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Richard PrinsIndependent · Lead Independent Director · Audit · Compensation (Chair)$117,500$130,004$129,996$0$0$377,500
Gayle DeflinIndependent · Audit (Chair)80,000130,004129,99600340,000
Howard LeeIndependent · Audit · Nominating/Governance73,500130,004129,99600333,500
Michael A. ZasloffIndependent · Compensation · Nominating/Governance71,000130,004129,99600331,000
Diane GerstIndependent · Nominating/Governance (Chair)67,750130,004129,99600327,750
Floyd F. PetersenIndependent · Compensation · Not standing for re-election65,000130,004129,99600325,000
David GaughIndependent · Compensation · Newly elected24,722130,017129,98800284,727
Mary Ziping LuoEmployee director · Board Chair000—00
Jacob LiawatidewiEmployee director000—00
William J. PetersEmployee director000—00
Jack Yongfeng ZhangEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$55,000
Annual equity retainer$260,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guidelineapplicable levels of ownership are required to be achieved by current executive officers, and expected to be achieved by non-employee directors, within five years of the date of the adoption of the Stock Ownership Guidelines.
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$499,472
Equity awards (grant-date value)$910,041
All other compensation$0
Total cost of the board$1,409,513

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Amphastar Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Amphastar Pharmaceuticals, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2PTC Therapeutics, Inc.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
3Halozyme Therapeutics, Inc.2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
4Supernus Pharmaceuticals, Inc.2025Jack Khattar1,036,0006,535,0297,031,545846,93015,501,557
5Corcept Therapeutics Inc.2025Joseph Belanoff1,182,333012,907,718015,303,551
6Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
7Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
8Pacira BioSciences, Inc.2025Frank Lee935,3089,215,5000738,81011,636,917
9ANI Pharmaceuticals, Inc.2025Nikhil Lalwani837,4097,848,71101,572,50010,278,620
10Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
11Amphastar Pharmaceuticals, Inc.2025Jack Yongfeng Zhang950,9113,301,9813,302,024361,0008,309,350
12ACADIA Pharmaceuticals, Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
13Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
14Prestige Consumer Healthcare, Inc.2026Ronald Lombardi1,003,5644,099,9590850,0006,004,547
15Emergent BioSolutions Inc.2025Joseph Papa1,037,3851,638,5001,191,5001,446,6405,321,147
16Ironwood Pharmaceuticals, Inc.2025Thomas McCourt867,568411,6960650,6761,948,390
17Collegium Pharmaceuticals, Inc.2025Vikram Karnani875,00000835,4061,715,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Amphastar Pharmaceuticals, Inc.not disclosedOptions 50 · RSU 50not disclosedWillis Towers Watson (WTW)
ACADIA Pharmaceuticals, Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
ANI Pharmaceuticals, Inc.185%RSU 75 · PSU 25Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences IndexPearl Meyer & Partners, LLC
Collegium Pharmaceuticals, Inc.127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Corcept Therapeutics Inc.Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Emergent BioSolutions Inc.107%Options 50 · PSU 50NoWTW
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Ironwood Pharmaceuticals, Inc.100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Pacira BioSciences, Inc.90%RSU 80 · PSU 20NoAon
Prestige Consumer Healthcare, Inc.68%PSU 75 · RSU 25Nonot disclosed
PTC Therapeutics, Inc.not disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
Supernus Pharmaceuticals, Inc.not disclosednot disclosedNoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Amphastar Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Jack Yongfeng Zhang (Chief Executive Officer, President, Chief Scientific Officer and Director) was the highest-paid executive at Amphastar Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $8,309,350.
How does Amphastar Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Jack Yongfeng Zhang's total compensation ranked at the 38th percentile of Amphastar Pharmaceuticals, Inc.'s disclosed peer group.
What is Amphastar Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Amphastar Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio was 135:1.
How did shareholders vote on Amphastar Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 91.85% of shareholders supported Amphastar Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Amphastar Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Amphastar Pharmaceuticals, Inc. reported total board compensation of $1,409,513 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jack Yongfeng ZhangDEF 14A2026-04-130001297184-26-000023Section “Fiscal 2025 Summary Compensation Table” · page 41. As printed: 8,309,350. Filing ↗machine: span 722923–722932
2Section 01, Mary Ziping LuoDEF 14A2026-04-130001297184-26-000023Section “Fiscal 2025 Summary Compensation Table” · page 41. As printed: 4,031,078. Filing ↗machine: span 757256–757265
3Section 01, William PetersDEF 14A2026-04-130001297184-26-000023Section “Fiscal 2025 Summary Compensation Table” · page 41. As printed: 3,238,682. Filing ↗machine: span 742493–742502
4Section 01, Rong ZhouDEF 14A2026-04-130001297184-26-000023Section “Fiscal 2025 Summary Compensation Table” · page 41. As printed: 2,542,634. Filing ↗machine: span 771418–771427
5Section 01, Jacob LiawatidewiDEF 14A2026-04-130001297184-26-000023Section “Fiscal 2025 Summary Compensation Table” · page 41. As printed: 2,037,856. Filing ↗machine: span 785508–785517
6Section 03, Mary Ziping Luo RSUDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r46 · c12 · span 992875–992881
7Section 03, William Peters RSUDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r34 · c12 · span 947242–947248
8Section 03, Jack Yongfeng Zhang RSUDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r21 · c12 · span 894623–894630
9Section 03, Rong Zhou RSUDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r59 · c12 · span 1039255–1039261
10Section 03, Jacob Liawatidewi RSUDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r70 · c12 · span 1083738–1083744
11Section 03, Jacob Liawatidewi OPTIONDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r69 · c6 · span 1077911–1077917
12Section 03, Rong Zhou OPTIONDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r58 · c6 · span 1033856–1033862
13Section 03, Jack Yongfeng Zhang OPTIONDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r20 · c6 · span 888826–888833
14Section 03, William Peters OPTIONDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r33 · c6 · span 941446–941452
15Section 03, Mary Ziping Luo OPTIONDEF 14A2026-04-130001297184-26-000023Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r45 · c6 · span 987078–987085
16Section 07, pay ratioDEF 14A2026-04-130001297184-26-000023Section “CEO Pay Ratio”. As printed: 135 : 1. Filing ↗machine: span 1328181–1328186
17Section 08, Richard PrinsDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 377,500. Filing ↗machine: t61 · r4 · c10 · span 337735–337868
18Section 08, Gayle DeflinDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t61 · r7 · c10 · span 346401–346534
19Section 08, Howard LeeDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 333,500. Filing ↗machine: t61 · r2 · c10 · span 331902–332035
20Section 08, Michael A. ZasloffDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 331,000. Filing ↗machine: t61 · r5 · c10 · span 340559–340692
21Section 08, Diane GerstDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 327,750. Filing ↗machine: t61 · r6 · c10 · span 343566–343699
22Section 08, Floyd F. PetersenDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 325,000. Filing ↗machine: t61 · r3 · c10 · span 334725–334858
23Section 08, David GaughDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 284,727. Filing ↗machine: t61 · r8 · c10 · span 349425–349558
24Section 08, Mary Ziping LuoDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 0. Filing ↗
25Section 08, Jacob LiawatidewiDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 0. Filing ↗
26Section 08, William J. PetersDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 0. Filing ↗
27Section 08, Jack Yongfeng ZhangDEF 14A2026-04-130001297184-26-000023Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, David Gaugh 2026-06-01Form 42026-06-030002075974-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Diane Gerst 2026-06-01Form 42026-06-030001611283-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Howard Lee 2026-06-01Form 42026-06-030001379941-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Gayle Deflin 2026-06-01Form 42026-06-030001866024-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Gayle Deflin 2026-06-01Form 42026-06-030001866024-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Diane Gerst 2026-06-01Form 42026-06-030001611283-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Michael A. Zasloff 2026-06-01Form 42026-06-030001033511-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Michael A. Zasloff 2026-06-01Form 42026-06-030001033511-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Howard Lee 2026-06-01Form 42026-06-030001379941-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Richard Prins 2026-06-01Form 42026-06-030001047579-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Richard Prins 2026-06-01Form 42026-06-030001047579-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, David Gaugh 2026-06-01Form 42026-06-030002075974-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Howard Lee 2026-06-02Form 42026-06-030001379941-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Anthony T. Pierce 2026-07-09Form 42026-07-130002141303-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Anthony T. Pierce 2026-07-09Form 42026-07-130002141303-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, William J. Peters 2026-08-07Form 42026-08-110001263136-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, William J. Peters 2026-08-07Form 42026-08-110001263136-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, William J. Peters 2026-08-07Form 42026-08-110001263136-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Richard Prins 2026-08-11Form 42026-08-120001047579-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Rong Zhou 2026-09-02Form 42026-09-030001645326-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Rong Zhou 2026-09-16Form 42026-09-170001645326-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Rong Zhou 2026-09-16Form 42026-09-170001645326-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Rong Zhou 2026-09-16Form 42026-09-170001645326-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, William J. Peters 2026-09-21Form 42026-09-230001263136-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
52Section 06, 2026 voteForm 8-K2026-06-030001297184-26-000038Item 5.07 · say-on-pay result. As reported: 91.85% (votes for as printed: 32,585,908). Filing ↗
53Section 06, 2025 voteForm 8-K2025-06-040001297184-25-000036Item 5.07 · say-on-pay result. As reported: 94.89% (votes for as printed: 35,585,000). Filing ↗
54Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
55Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
56Section 09b board cost (computed)Computed——Cash 499,472 + equity 910,041 + all other 0 = 1,409,513, summed across the director compensation table rows.machine: formula: Σ = 1,409,513
57Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
58PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗
59Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
60Supernus Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-300001104659-26-053111CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604
61Corcept Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics Inc.'s own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
62Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
63Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
64Pacira BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
65ANI Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-090001023024-26-000039CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154
66Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
67Amphastar Pharmaceuticals, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-130001297184-26-000023CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932
68ACADIA Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗
69Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
70Prestige Consumer Healthcare, Inc., Section 10b CEO totalDEF 14A2026-06-290001295947-26-000021CEO total compensation as printed in Prestige Consumer Healthcare, Inc.'s own proxy. As printed: 6,004,547. Filing ↗machine: span 1927946–1927955
71Emergent BioSolutions Inc., Section 10b CEO totalDEF 14A2026-03-200001367644-26-000033CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. Filing ↗machine: t155 · r3 · c15 · span 906918–906927
72Ironwood Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
73Collegium Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceuticals, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
74Section 10a, Prestige Consumer Healthcare, Inc. reciprocityDEF 14A—0001295947-26-000021Prestige Consumer Healthcare, Inc. names Amphastar Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
75Section 10a, ACADIA Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
76Section 10a, Collegium Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-024063Collegium Pharmaceuticals, Inc. names Amphastar Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
77Section 10a, Emergent BioSolutions Inc. reciprocityDEF 14A—0001367644-26-000033Emergent BioSolutions Inc. names Amphastar Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
78Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
79Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
80Section 10a, Ironwood Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
81Section 10a, Pacira BioSciences, Inc. reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
82Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
83Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-023923Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
84Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
85Section 10a, ANI Pharmaceuticals, Inc. reciprocityDEF 14A—0001023024-26-000039ANI Pharmaceuticals, Inc. names Amphastar Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
86Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗
87Section 10a, Supernus Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-053111Supernus Pharmaceuticals, Inc. names Amphastar Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
88Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Amphastar Pharmaceuticals, Inc.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Amphastar Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
AMPH Peer Teardown Report